Predictive Utility of DASIMAR as a Prognostic Biomarker in Acute-on-chronic Liver Failure (ACLF)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients with acute on chronic liver failure have a risk of developing multiorgan failure and a high mortality. The current scoring systems defining the outcome of patients with acute decompensation of cirrhosis fail to identify patients that progress to Acute-on-chronic liver failure (ACLF).
The aim of the study is to evaluate if one can identify these patients early on with the proposed biomarkers: dimethylarginines and ischemia modified albumin.
| Condition |
|---|
|
Liver Cirrhosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Predictive Utility of the Dimethylarginines and Ischemia Modified Albumin as Prognostic Biomarkers in Patients With Acute-on-chronic Liver Failure |
- Progress to ACLF [ Time Frame: hours, days ] [ Designated as safety issue: No ]
- Prognosticate ACLF [ Time Frame: Days ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
RNA
| Estimated Enrollment: | 700 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | November 2010 |
| Estimated Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Acute decompensation of cirrhosis
acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.
|
Detailed Description:
Patients with acute-on-chronic liver failure (ACLF) are at risk of multiorgan failure and high mortality. Recent data suggest that patients with decompensated liver cirrhosis have higher ADMA (asymmetrical dimethylarginine) levels compared to compensated cirrhosis and plasma ADMA levels correlate with severity of liver dysfunction and inflammation. There is also an increase in symmetric dimethylarginine (SDMA), a stereo-isomer of ADMA, which is largely excreted by the kidney. Plasma SDMA levels have been shown to be associated with patients
progressing to renal failure. In a pilot study by our group involving 52 patients with acute decompensation of chronic liver disease, we showed an increase in the summed product of ADMA and SDMA, which we termed dimethylarginine score ('DAS'): This was shown to have a good predictive utility for outcome in this small group of patients (AUROC=0.89).
Furthermore, we and others have shown that albumin of patients with advanced liver disease has widespread abnormalities. The amount of albumin that is found to have reduced metal binding capacity as a consequence of oxidative damage is termed Ischemia Modified Albumin (IMA).
Our data shows that patients with ACLF who die have a significantly increased IMA/serum albumin ratio (IMAR). The summation of these two pathologically relevant biomarkers (DAS+IMAR) we termed DASIMAR and found this score to have a better predictive utility than DAS alone (AUROC:0.91).
Primary objective : To identify the patients early on that progress to ACLF which would facilitate a goal directed therapeutic approach.
Secondary objective : Generation of this dataset will further define and enable prognostication of ACLF. If this study reveals a role for these biomarkers in patients with ACLF, commercial development of simple kits may be possible.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inpatients with acute clinical deterioration of cirrhosis.
Inclusion Criteria:
- All patients with an acute clinical decompensation of presumed cirrhosis (elevated bilirubin >85 µmol/L, or/and increasing ascites or/and hepatic encephalopathy < grade 2) related to a clear precipitating event (e.g. infection, bleeding, alcoholic hepatitis, exposure to hepatotoxin)
Exclusion Criteria:
- Admission for reasons other than decompensation of cirrhosis (other co-morbid diseases, especially established cardiovascular or renal disease (U/S).
- Malignancy (extra-hepatic or a hepatocellular carcinoma).
- Patients who have undergone major surgery or have unsolved surgical problems.
- Pregnancy
Contacts and Locations| Contact: Rajeshwar P Mookerjee, BScMRCPPhD | 02076796516 | r.mookerjee@ucl.ac.uk |
| Contact: Naina Shah, MBBSMRCP | 02076796516 | naina.shah@ucl.ac.uk |
| United Kingdom | |
| University College London Hospital | Recruiting |
| London, United Kingdom, WC1E 6HX | |
| Contact: Rajeshwar P Mookerjee, BScMRCPPhD 02076796516 | |
| Contact: Naina Shah, MBBSMRCP 02076796516 | |
| Principal Investigator: | Rajeshwar P Mookerjee, BScMRCPPhD | University College London Hospital |
More Information
No publications provided
| Responsible Party: | Dr Rajeshwar P Mookerjee, University College London Hospitals |
| ClinicalTrials.gov Identifier: | NCT01071746 History of Changes |
| Other Study ID Numbers: | 08/HO714/8 |
| Study First Received: | February 18, 2010 |
| Last Updated: | February 18, 2010 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Additional relevant MeSH terms:
|
Liver Cirrhosis Fibrosis Liver Failure End Stage Liver Disease |
Liver Diseases Digestive System Diseases Pathologic Processes Hepatic Insufficiency |
ClinicalTrials.gov processed this record on May 16, 2013